Breaking News

Luxa Biotechnology Receives $4M Grant to Support Study of RPESC-RPE-4W Transplantation

The funding will accelerate manufacturing and clinical activities based in California.

Author Image

By: Charlie Sternberg

Associate Editor

Luxa Biotechnology, a joint venture between Y2 Solution Co. Ltd. and the Neural Stem Cell Institute (NSCI), has received a $4 million grant from the California Institute for Regeneration Medicine (CIRM) to support the ongoing Phase 1/2a study of RPESC-RPE-4W transplantation for the treatment of dry age-related macular degeneration (dry AMD). The funding will accelerate manufacturing and clinical activities based in California.   RPESC-RPE-4W is a cell product derived from adult retinal pigment...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters